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Background: Lumefantrine is the mainstay of anti-malarial combination therapy in most endemic countries presently.
However, it cannot be used alone owing to its long onset time of action. CDRI 97–78 is a promising trioxane-derivative
anti-malarial candidate that is currently being investigated as a substitute for artemisinin derivatives owing to their
emerging resistance.
Methods: In the present study, a sensitive, simple and rapid high-performance liquid chromatography coupled
with positive ion electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed for
the simultaneous determination of lumefantrine and CDRI 97-78’s metabolite, 97–63, in rat plasma using halofantrine
as an internal standard. Lumefantrine and 97–63 were separated on a Waters Atlantis C18 (4.6 × 50 mm, 5.0 μm)
column under isocratic condition with mobile phase consisting of acetonitrile: methanol (50:50, v/v) and ammonium
formate buffer (10 mM, pH 4.5) in the ratio of 95:5 (v/v) at a flow rate of 0.65 mL/min.
Results: The method was accurate and precise within the linearity range 3.9-500 ng/mL for both lumefantrine and
97–63 with a correlation coefficient (r2) of ≥0.998. The intra- and inter-day assay precision ranged from 2.24 to
7.14% and 3.97 to 5.90%, and intra- and inter-day assay accuracy was between 94.93 and 109.51% and 96.87 and
108.38%, respectively, for both the analytes. Upon coadministration of 97–78, the relative bioavailability of lumefantrine
significantly decreased to 64.41%.
Conclusions: A highly sensitive, specific and reproducible high-throughput LC-ESI-MS/MS assay was developed and
validated to quantify lumefantrine and CDRI 97–78. The method was successfully applied to study the effect of oral
co-administration of lumefantrine on the pharmacokinetics of 97–78 in male Sprague–Dawley rats and vice versa.
Co-administration of 97–78 significantly decreased the systemic exposure of lumefantrine.
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Artemether-lumefantrine (AL) is a first-line artemisinin
combination therapy (ACT) recommended by WHO for
the treatment of uncomplicated Plasmodium falciparum
malaria [1]. The drugs are commercially available as a
fixed dose combination in form of tablets, Coartem® and
Riamet®. The combination of a short-acting and a long-
acting drug is apt for treatment of malaria cases since
the short-acting partner kills most of the circulating par-
asites while the long-acting drug clears the remaining
more slowly, thus preventing recrudescence. Lumefantrine
(LUME) (previously known as benflumetol) was synthe-
sized in the 1970s by the Academy of Military Medical
Sciences in Beijing, China. It is a racemic fluorene deriva-
tive, named 2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-
benzylidene)- 9H-fluoren-4-yl]-ethanol [2,3]. It is the
long-acting partner drug of the artemisinin derivative
artemether, in this ACT. However, recently reports of
artemisinin resistance have emerged from the Greater
Mekong Subregion of Myanmar, Cambodia, Thailand,
and Vietnam with increased parasite clearance times [1,4].
Owing to the emerging resistance to artemisinin deriva-
tives as well as their low oral bioavailability, there is the
need to find novel anti-malarial agents that are devoid of
such drawbacks and are more affordable to serve as an
artemisinin alternative. To find a suitable fast-acting
partner drug for LUME, CSIR-Central Drug Research
Institute (India) (CDRI) has developed a series of trioxane
anti-malarial compounds in its drug discovery programme
[5,6]. One of the most promising compounds among these
is CDRI candidate drug molecule 97–78 (Figure 1), whichFigure 1 Structural representation of LUME, halofantrine, CDRI 97–78, andhas been identified for development as a suitable alter-
native for artemisinin derivatives for use against drug-
resistant P. falciparum and cerebral malaria cases. It is
currently under Phase 1 clinical trials in licensing agree-
ment with IPCA Pharmaceuticals Ltd, Mumbai, India. It
is a water-soluble synthetic 1,2,4-trioxane derivative ac-
tive in both rodent and monkey malaria models. This
CDRI drug candidate has undergone preclinical efficacy,
regulatory toxicity and pharmacological studies and has
been found safe. Its Phase 1 safety trials have been com-
pleted in 50 volunteers and Phase 1 single dose pharmaco-
kinetics in 16 volunteers [7]. In vivo, 97–78 gets rapidly
and completely converted into its active metabolite 97–63
(Figure 1), which is quantified in the biological system [8].
The preclinical pharmacokinetics of LUME (Figure 1)
has been established previously [9-11]. In the present re-
port, a simple, sensitive and specific liquid chromatog-
raphy is described coupled with positive ion electrospray
ionization-tandem mass spectrometry (LC-ESI-MS/MS)
method developed and validated for the simultaneous
quantification of LUME and 97–63 in 100 μL rat plasma
using halofantrine (Figure 1) as an internal standard (IS).
The validated method was then applied to study the pre-
clinical pharmacokinetic interaction of LUME and CDRI




LUME and halofantrine (IS) were a generous gift from
Ipca Laboratories Ltd, Mumbai, India. 97–78 and 97–63its metabolite 97–63.
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Central Drug Research Institute, Lucknow, India. High
performance liquid chromatography (HPLC) grade aceto-
nitrile was purchased from Sisco Research Laboratories
(SRL) Pvt Ltd, Mumbai, India. HPLC grade methanol was
purchased from Thomas Baker Pvt Ltd, Mumbai, India.
Ammonium formate and glacial acetic acid AR were pur-
chased from E Merck Ltd, Mumbai, India. Sodium car-
boxy methyl cellulose (CMC) was purchased from Sigma
Aldrich Ltd, St Louis, USA. Ultra-pure water was obtained
from a Sartorius Arium 611 system. Heparin sodium in-
jection IP (1,000 IU/mL, Biologicals E Ltd, Hyderabad,
India) was purchased from local pharmacy.
Animals and prerequisites
Blank, drug-free, plasma samples were collected from
adult, healthy male Sprague–Dawley (SD) rats at the
Division of Laboratory Animals (DOLA) of Central Drug
Research Institute, Lucknow, India. Plasma was obtained
by centrifuging the heparinized blood (25 IU/mL) at
2,000 × g for 10 min at 20°C. Prior approval from the In-
stitutional Animal Ethics Committee (IAEC) was sought
for maintenance, experimental studies, euthanasia, and
disposal of carcass of animals.
Instrumentation and chromatographic conditions
HPLC system consisting of Series 200 pumps and auto-
sampler with temperature-controlled Peltier-tray (Perkin-
Elmer Corp, Norwalk, CT, USA) was used to inject 10-μL
aliquots of the processed samples on a Waters Atlantis
C18 column (4.6 × 50 mm, 5.0 μm). The system was run
in isocratic mode with mobile phase consisting of aceto-
nitrile: methanol (50:50, v/v) and 10 mM ammonium for-
mate buffer (pH = 4.5) in the ratio of 95:5 (v/v) at a flow
rate of 0.65 mL/min. Mobile phase was duly filtered
through 0.22 μm Millipore filter (Billerica, MA, USA) and
degassed ultrasonically for 15 min prior to use. Separa-
tions were performed at room temperature. Auto-sampler
carry-over was determined by injecting the highest cali-
bration standard then a blank sample. 97–78 rapidly
converted to 97–63 in plasma [8], hence, 97–63 was
quantified instead of 97–78.
Mass spectrometric detection was performed on an
API 4000 mass spectrometer (Applied Biosystems/MDS
Sciex, Toronto, Canada) equipped with an API electro-
spray ionization (ESI) source. The ion spray voltage was
set at 5,500 V. The instrument parameters: nebulizer
gas, curtain gas, auxillary gas, and collision gas, were set
at 40, 13, 50, and 10, respectively. Compounds parame-
ters: declustering potential (DP), collision energy (CE),
entrance potential (EP), and collision exit potential
(CXP) were 80, 33, 10, 10 V, 50, 30, 4, 10 V, and 90, 33,
6, 8 V for LUME, 97–63 and IS, respectively. Zero air
was used as source gas while nitrogen was used as bothcurtain and collision gas. The mass spectrometer was
operated at ESI positive ion mode and detection of the
ions was performed in the multiple reaction monitoring
(MRM) mode, monitoring the transition of m/z 529 pre-
cursor ion [M +H]+ to the m/z 511.3 product ion for
LUME, m/z 418.2 precursor ion [M +H]+ to the m/z
119.1 product ion for 97–63 and m/z 502 precursor ion
[M+H]+ to the m/z 142.2 product ion for IS. Quadrupole
1 and quadrupole 3 were maintained at unit resolution
and dwell time was set at 200 ms. Data acquisition and
quantitation were performed using analyst software ver-
sion 1.4.1 (Applied Biosystems/MDS Sciex Toronto, Canada).
Preparation of standard and quality control samples
Primary stock solutions of LUME, 97–63 and IS were pre-
pared by dissolving the compounds in acidified methanol
(1% glacial acetic acid) to achieve desired concentration of
1 mg/mL. Working standard solutions of LUME and
97–63 were prepared by combining the aliquots of each
primary stock solution, and diluting with methanol. A
working stock solution of IS (50 ng/mL) was prepared
by diluting an aliquot of primary stock solution with
acetonitrile. All the stock solutions were stored at 4°C
until analysis and were found to be stable up to six months.
Calibration standards of LUME and 97–63 (3.9, 7.8, 15.6,
31.25, 62.5, 125, 250, and 500 ng/mL) were prepared by
spiking 90 μL of pooled, drug-free, rat plasma with the ap-
propriate working standard solution of the analytes (10 μL).
Quality control (QC) samples were prepared by individually
spiking control rat plasma at four concentration levels
(3.9 ng/mL (lower limit of quantitation, LLOQ), 10 ng/mL
(QC low), 100 ng/mL (QC medium) and 400 ng/mL
(QC high)) and stored at −70 ± 10°C until analysis.
Recovery
The extraction recovery of analytes through protein pre-
cipitation extraction procedure was determined by com-
paring the peak areas of pre-spiked extracted plasma
standard QC samples (n = 6) to those of the post-spiked
standards at equivalent concentrations. Recoveries of
LUME and 97–63 were determined at three concentra-
tion levels, LLOQ, QC low and QC high concentrations:
3.9, 10 and400 ng/mL, whereas the recovery of the IS
was determined at a single concentration of 50 ng/mL.
Recovery %ð Þ ¼ Concentration of pre−spiked sample
Concentration of post−spiked sample
 100
Sample preparation
All frozen study samples and QC samples were thawed
and allowed to equilibrate at room temperature prior to
analysis. A simple protein precipitation method was followed
for extraction of analytes from rat plasma. To 100 μL of
plasma in a tube, 200 μL of IS solution (50 ng/mL in
Wahajuddin et al. Malaria Journal  (2015) 14:172 Page 4 of 9acetonitrile), was added and vortexed for 10 min followed
by centrifugation for 10 min at 15,000 × g. The super-




The specificity and selectivity has been studied by using
independent plasma samples from six different rats to
investigate the potential interferences at the chromato-
graphic peak region for analyte and IS, using the proposed
extraction procedure and chromatographic-MS conditions.
Matrix effect
Pooled rat plasma from six different rats was used. The
effect of rat plasma constituents over the ionization of
LUME, 97–63 and IS was determined by comparing theFigure 2 Typical MRM chromatograms of LUME and 97–63 in rat plasma. (
and 97–63 at LLOQ (3.9 ng/mL) and IS.responses of the post-extracted plasma standard QC
samples (low and high) (n = 6) with the response of ana-
lytes from neat standard samples. The neat samples of
equivalent concentrations were prepared by spiking
equal volume of the working stock solutions in mobile
phase. The matrix effect was calculated as:
%ME ¼ Response of the post‐extracted spiked sample
Response of the equivalent neat standard sample
 100
Calibration curve
The plasma calibration curve was constructed using
eight calibration standards (3.9-500 ng/mL for LUME
and 97–63) prepared by spiking 90 μL of pooled, drug-
free rat plasma with the appropriate working standard
solution of the analytes (10 μL).A) a drug-free blank plasma, (B) drug-free plasma spiked with LUME
Table 1 Intra-day assay precision and accuracy for LUME and 97–63 in rat plasma (n = 6)
LUME (ng/mL) 97-63 (ng/mL)
3.9 10 100 400 3.9 10 100 400
Day 1
Mean 3.9 9.6 97.4 387.3 4.1 10.2 104.0 405.2
SD 0.23 0.22 6.16 16.61 0.28 0.46 4.75 14.16
Precision (%)a 5.78 2.24 6.33 4.29 6.76 4.54 4.56 3.50
Accuracy (%)b 100.17 96.20 97.35 96.83 104.32 109.12 104.04 101.29
Day 2
Mean 3.7 9.9 97.9 397.5 3.8 9.9 102.8 415.3
SD 0.27 0.55 6.93 11.74 0.23 0.53 3.99 9.35
Precision (%)a 7.14 5.51 7.07 2.95 6.01 5.27 3.88 2.25
Accuracy (%)b 95.90 99.47 97.92 99.38 99.40 106.52 102.78 103.83
Day 3
Mean 3.8 9.5 103.0 415.0 3.8 10.3 104.3 386.5
SD 0.18 0.48 4.00 18.32 0.18 0.49 4.18 10.89
Precision (%)a 4.81 5.06 3.88 4.41 4.81 4.81 4.01 2.82
Accuracy (%)b 98.25 94.93 103.00 103.75 103.93 109.51 104.33 96.63
a Expressed as % RSD = (SD/mean) × 100.
b Calculated as (mean determined concentration/nominal concentration) × 100.
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The intra-day assay precision and accuracy were esti-
mated by analysing six replicates at four different QC
levels, i.e., 3.9, 10, 100, and 400 ng/mL, for LUME and
97–63. The inter-day assay precision was determined by
analysing the four levels QC samples on three different
runs. The criteria for acceptability of the data included
accuracy within ±15% deviation from the nominal values
and a precision of within ±15% relative standard devi-
ation (RSD), except for LLOQ, where it should not ex-
ceed ±20% for accuracy as well as precision.
Stability experiments
All stability studies were conducted at two concentration
levels, i.e., QC low and QC high, using six replicates at
each concentration levels. Replicate injections of proc-
essed samples were analysed up to 18 hrs to establish
auto-sampler stability (AS) of analytes and IS at 4°C.
The peak areas of analyte and IS obtained at initial cycle
were used as the reference to determine the stability atTable 2 Inter-day assay precision and accuracy for LUME and
LUME (ng/mL)
3.9 10 100 40
Meana 3.8 9.7 98.1 39
SD 0.23 0.46 5.37 18
Precision (%)b 5.90 4.72 5.48 4.7
Accuracy (%)c 98.11 96.87 99.42 99
a n = 18; three days with six replicates per day.
b Expressed as % RSD = (SD/mean) × 100.
c Calculated as (mean determined concentration/nominal concentration) × 100.subsequent points. The stability of LUME and 97–63 in
the biomatrix during 6 hrs of exposure at room temperature
in rat plasma (bench top (BT)) was determined at ambient
temperature (25 ± 2°C). Freeze/thaw (FT) stability was evalu-
ated up to three cycles. In each cycle, samples were frozen
for at least 12 hrs at −70 ± 10°C. Freezer stability of both ana-
lytes in rat plasma was assessed by analysing the QC samples
stored at −70 ± 10°C for at least 15 days. Samples were
considered to be stable if assay values were within the
acceptable limits of accuracy (i.e., ±15% deviation) and
precision (i.e., ±15% RSD).
Dilution integrity
The dilution integrity experiment was performed with
an aim to validate the dilution test to be carried out on
higher analyte concentrations (above the upper limit of
quantification), which may be encountered during real
subject samples analysis. Dilution integrity experiments
were carried out by 20 times dilution of plasma samples
containing 8,000 ng/mL of LUME and 97–63 with blank97–63 in rat plasma
97-63 (ng/mL)
0 3.9 10 100 400
9.9 4.0 10.2 103.7 402.3
.94 0.23 0.48 4.11 16.45
4 5.77 4.75 3.97 4.09
.99 102.55 108.38 103.72 100.58
Table 3 Stability of LUME and 97–63 in rat plasma
LUME 97-63
Meana SD Precisionb (%) Accuracyc (%) Meana SD Precisionb (%) Accuracyc (%)
10 (ng/mL)
0 hr (for all) 9.6 0.22 2.24 96.20 10.2 0.46 4.54 109.12
24 hrs (AS) 9.9 0.40 4.05 103.72 4.3 0.16 3.74 104.67
6 hrs (BT) 9.8 0.69 7.01 101.73 3.8 0.16 4.30 93.85
FT-3 9.6 0.74 7.74 99.48 3.9 0.13 3.34 98.16
15 days at −70°C 9.6 0.24 2.49 105.73 4.1 0.12 2.92 100.47
400 (ng/mL)
0 hr (for all) 387.3 16.61 4.29 96.83 405.2 14.16 3.50 101.29
24 hrs (AS) 393.2 17.62 4.48 101.51 407.0 16.16 3.97 100.45
6 hrs (BT) 391.3 19.01 4.86 101.03 388.3 14.47 3.73 95.85
FT-3 413.5 12.34 2.98 106.78 404.3 6.15 1.52 99.79
15 days at −70°C 397.2 9.28 2.34 102.54 400.0 8.34 2.09 98.72
a Back calculated plasma concentrations (n = 6).
b Expressed as % RSD = (SD/mean) × 100.
c Calculated as (mean determined concentration/nominal concentration) × 100.
Figure 3 Linear plots of plasma concentration LUME after oral
administration of LUME alone or in combination with
97–78 (means ± SD).
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high)of LUME and 97–63.
Application to interaction study
Study was performed in male Sprague–Dawley rats (n = 5,
weight range 200–220 g). The rats were fasted overnight
(14–16 hrs) prior to the experiment but given free access
to water. Rats were divided into three groups (n = 5 each):
two control groups (LUME, 10 mg/kg, oral, suspension in
0.25% sodium CMC and 97–78, 70 mg/kg, oral, suspen-
sion in 0.25% sodium CMC), and one co-administration
group (70 mg/kg of oral 97–78 and 10 mg/kg of oral
LUME). Blood samples (approximately 0.25 mL) were col-
lected from the retro-orbital plexus into heparinized
microfuge tubes at 0.25, 0.50, 1, 3, 6, 9, 11, 13, 15, 24, 48,
72, and 120 hrs post-dosing and plasma was harvested by
centrifuging the blood at 15,000xg for 10 min and stored
frozen at −70 ± 10°C until bio-analysis.
Pharmacokinetic and statistical analysis
Plasma data were subjected to non-compartmental
pharmacokinetics analysis using WinNonlin (version 5.1,
Pharsight Corp, Mountain View, CA, USA). The observed
maximum plasma concentration (Cmax) and the time to
reach the maximum plasma concentration (Tmax) were
obtained by visual inspection of the experimental data.
Area under the plasma concentration-time curve from
time zero to the last quantifiable concentration (AUC0-t)
was calculated using linear trapezoidal rule. The total area
under the plasma concentration–time curve from time
zero to time infinity (AUC0-∞) was calculated as the sum
of AUC0-t and Clast/kel, where, Clast represents the last
quantifiable concentration and Kel represents the terminalphase rate constant. The apparent elimination half-life
(t1/2) was calculated as 0.693/kel and the kel was esti-
mated by linear regression of the plasma concentrations
in the log-linear terminal phase. The clearance (Cl/F);
where F represents the oral bioavailability, was calcu-
lated as dose/AUC, and the volume of distribution (Vd/F)
was calculated as (Cl/F)/kel. The data is presented as a
mean ± SD. The pharmacokinetic parameters were com-
pared using Student’s t test. A P-value of <0.05 was con-
sidered significant. The relative bioavailability (RB %) was
calculated as follows:
Relative bioavailability RB%ð Þ ¼ AUC coadimin
AUC control
 100
Table 4 The pharmacokinetic parameters of LUME and 97–78 in rats (n = 5 each)
Parameters Control LUME with 97-78
LUME (10 mg/kg) 97-78 (70 mg/kg) LUME (10 mg/kg) 97-78 (70 mg/kg)
AUC0-t (h*μg/mL) 16.52 ± 2.96 9.10 ± 1.48 10.64 ± 0.71
* 8.04 ± 1.26
AUC0-∞ (h*μg/mL) 17.42 ± 3.29 9.15 ± 1.46 11.02 ± 0.66
* 8.15 ± 1.26
Cmax (μg/mL) 1.81 ± 0.75 1.35 ± 0.17 1.92 ± 0.62 1.79 ± 0.69
Tmax (h) 3.75 ± 1.50 2.2 ± 1.09 4 ± 2.45 0.5
#
Vd/F (L/kg) 39.45 ± 6.26 106.05 ± 30.57 62.73 ± 8.40
* 142.03 ± 28.13
CL/F (L/h/kg) 0.59 ± 0.09 7.81 ± 1.26 0.91 ± 0.06 * 8.76 ± 1.38
t1/2 (h) 46.94 ± 6.52 9.27 ± 1.33 47.82 ± 6.48 11.25 ± 1.45
RB% – – 64.41* 88.35
All data are expressed as mean ± SD.
*P <0.05, vs LUME control; #P <0.05, vs 97–78 control.
Figure 4 Linear plots of plasma concentration of CDRI 97–63 after
oral administration of CDRI 97–78 alone or in combination with
LUME (means ± SD).
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LC-MS/MS optimization
It was important to optimize extraction technique, chroma-
tographic conditions and mass spectrometry parameters to
develop and validate a selective and rapid assay method for
simultaneously quantitation of LUME, 97–63 and IS in rat
plasma. Protein precipitation was chosen as the sample
preparation method. Several organic solvents, including
acetic acid, trichloroacetic acid, acetonitrile and metha-
nol, were investigated as the precipitation extraction
solvents. Acetonitrile was chosen because of higher ex-
traction efficiency for LUME, 97–63 and IS, and much
cleaner samples than other solvents. Several column types
and chromatographic conditions were tested in order to
develop a short, robust and sensitive analytical method. A
short (4.6 × 50 mm, 5.0 μm) Waters Atlantis C18 column
with mobile phase consisting of acetonitrile: methanol
(50:50, v/v) and 10 mM ammonium formate buffer
(pH 4.5) in the ratio of 95:5 (v/v) at a flow rate of 0.65 mL/
min provided the best compromise between selectivity and
speed of analysis. The overall analysis time was 6.0 min. No
carry-over was observed, as indicated by the lack of LUME
and 97–63 and halofantrine (IS) peaks in the blank sample.
Mass parameters were optimized by infusing standard
analyte solution (100 ng/mL) into the mass spectrometer.
In order to optimize ESI conditions for LUME, 97–63 and
IS, quadrupole full scans were carried out in positive ion
detection mode. During a direct infusion experiment, the
mass spectra for LUME, 97–63 and IS revealed peaks at
m/z 529, 418.2 and 502, respectively, as protonated mo-
lecular ions [M +H]+. Following detailed optimization of
mass spectrometry conditions (provided in instrumenta-
tion and chromatographic conditions section) m/z 529
precursor ion [M+H]+ to the m/z 511.3 product ion for
LUME, m/z 418.2 precursor ion [M+H]+ to the m/z
119.1 product ion for 97–63 and m/z 502 precursor ion
[M+H]+ to the m/z 142.2 product ion for IS was used for
the quantitation purpose.Recovery
The extraction recovery of the LUME and 97–63 ranged
from 94.63 to 109.56%, and the extraction recovery of the
internal standard was 93.26% (See Additional file 1).
Validation procedures
The procedures were followed as per US FDA guidelines [12].
Specificity and matrix effect
In the present study, the specificity and selectivity has
been studied by using independent plasma samples from
six different rats. Figure 2 shows a typical chromatogram
for the drug-free plasma (Figure 2A) and drug-free plasma
spiked with LUME and 97–63 at LLOQ and IS (Figure 2B).
As shown in Figure 2A, there is no significant interference
from plasma found at retention time of either the analyte
or the IS. The ion suppression or enhancement by plasma
was less than 13.25% for the analytes and 18.5% for IS which
demonstrated that the matrix effects do not cause quantita-
tion bias. Therefore, matrix effect could be negligible under
the experimental conditions (See Additional file 1).
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The plasma calibration curve was constructed using
eight calibration standards (3.9-500 ng/mL). The average
regression (n = 3) was found to be ≥0.998. The percent-
age accuracy observed for the mean of back-calculated
concentrations for three calibration curves was within
93.89 to 106.53, while the percentage precision values
ranged from 1.39 to 9.00 for both the analytes.
Accuracy and precision
Accuracy and precision data for intra- and inter-day
plasma samples are presented in Tables 1 and 2. The
assay values on both the occasions (intra- and inter-day)
were found to be within the accepted variable limits.
Stability
The predicted concentrations for LUME and 97–63 at
10 and 400 ng/mL samples deviated within the nominal
concentrations in a battery of stability tests: AS (18 hrs),
BT (6 hrs), repeated three FT cycles (FT-3) and at −70 ±
10°C for at least for 15 days (Table 3). The results were
found to be within the assay variability limits during the
entire process.
Dilution integrity
The percentage accuracy of diluted QCs was in the range
of 94.56 to 107.68, while percentage precision values
ranged from 0.89 to 7.52 for both the analytes. The results
suggested that samples with concentrations greater than
the upper limit of calibration curve could be re-analysed
by appropriate dilution.
Application to interaction study
The rat plasma samples generated following administration
of LUME and 97–78 were analysed by the newly developed
and validated method along with QC samples. The mean
plasma concentration-time profiles of LUME administered
(10 mg/kg) alone or in combination with 97–78 (70 mg/kg)
orally in rats, are shown in Figure 3. Table 4 summarizes
the pharmacokinetic parameters of LUME and 97–78. The
presence of 97–78 significantly (p <0.05) decreased the
AUC0-∞ (63.26%) of orally administered LUME. Consequently,
the RB% of LUME in the presence of 97–78 is remarkably de-
creased (64.41%) compared to the LUME alone. The Tmax
and Cmax were not significantly altered by 97–78. LUME
clearance (Cl/F) was increased by 64.84% and Vd/F increased
by 62.89% with 97–78 co-administration. As both apparent
CL/F and apparent Vd/F were increased almost proportionally,
there was no significant effect on the t1/2 of LUME in pres-
ence of 97–78 (47.82 vs 46.94 hrs; p > 0.05).
Mean plasma concentration-time profiles of 97–78 are
shown in Figure 4. The Tmax of 97–78 was significantly
decreased by LUME (2.2 vs 0.5 hrs; p < 0.05). LUME had
no significant effect on other PK parameters of 97–78(Table 4). Further studies are required to understand the
mechanistic basis of alterations upon per-oral co-
administration of anti-malarial as potential combina-
tions. These results should be taken into consideration
while designing clinical proof of concept pharmacody-
namic studies and while designing dosage regimen.
Conclusion
In this study, a highly sensitive, specific, reproducible,
and high-throughput LC–ESI-MS/MS assay has been
developed and validated to quantify LUME and CDRI
97–78 following protein precipitation extraction tech-
nique from rat plasma, for the first time using halofantrine
as IS. Due to good sensitivity (LLOQ −3.9 ng/mL for both
LUME and 97–63) of the assay and its short run time of
6 min, it offers a suitable platform for the determination
of LUME and 97–63 in preclinical studies. The results of
the interaction study show that there are potential chances
of pharmacokinetic interactions between long-acting
LUME and short-acting 97–78.
Additional file
Additional file 1: Table S1. Recovery and matrix effect for LUME, 97–63
and IS in rat plasma.
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